Welcome to our wonderful forum. I am not famililar with
the story on Christel; but I do have the rest of the information you
requested. Your friend, lillian
********* May 26, 1998 Source: Business Wire
Burzynski Research Institute Announces Interim Cancer
Drug Results
HOUSTON--(BUSINESS WIRE) via NewsEdge
Corporation -- Burzynski Research Institute, Inc. (OTC bulletin board stock
symbol:BZYR) today announced interim results from Phase II clinical trials of
its experimental cancer drugs, Antineoplastons, in the treatment of brain
cancer.
Used in combination, Antineoplastons A10 and AS2-1 produced
responses (complete tumor elimination or greater than 50% reduction in tumor
size) in 43 of 178 evaluable patients, for a response rate of 24.1 per cent. An
additional 72 patients (40.5% of evaluable patients) experienced stable disease,
meaning their tumors did not progress, or shrink more than 50%.
The two
largest groups of patients suffered from glioblastoma multiforme (36.5%) and
astrocytoma-type tumors (32%). Approximately 10% of patients had
difficult-to-treat brain stem tumor locations.
"These results are
exciting because conventional treatments are generally considered ineffective
against primary malignant brain tumors," said Stanislaw Burzynski MD, PhD, the
firm's founder and CEO. "What makes it all the more exciting is that these are
responses in human brain cancers that are normally considered incurable and
fatal. The patients with stable disease give us hope that even the most
intractable cancers may become manageable chronic diseases."
The drugs
represent a type of gene therapy that targets the signal path of errant ras
oncogenes and the p53 tumor suppressor gene. Malfunctions in these genes are
believed responsible for up to 60% of all human cancers.
"The drugs
function as chemical microswitches, turning off the signal that makes cancer
cells multiply endlessly, at the same time turning on the signal that tells the
cells to undergo programmed cell death, or apoptosis," Burzynski said. "This is
an information-age approach to cancer treatment because it uses information,
rather than energy, to do the job."
Antineoplastons were well-tolerated
by most patients. The most commonly reported adverse event was an elevated level
of serum sodium. 1.3% of all clinical trial patients had elevations of 180 mEq/L
or higher at or around the time of their deaths. Other adverse events included
nausea, vomiting, allergic skin reactions, joint and muscle pain, and fatigue,
and occurred in a small percentage of patients.
Burzynski believes the
company now has enough data to apply for FDA approval. An NDA (New Drug
Application) could be filed by the end of this year.
CONTACT: Burzynski
Research Institute Inc., Houston | Dr. Stanislaw Burzynski, 281/597-0111 |
www.cancermed.com | www.burzynskipatientgroup.org | or | Dean Mouscher,
773/404-0486
--------------------------------------------------------------------------------
My friend was just diagnosed with an
Anaplastic Astrocytoma a few weeks ago. He has already had surgery and
is about to start Radiation. I read the story about Christel and was
wondering how her battle was going. This email really touched my
heart. I was also interested in finding out about Dr. Burzynski's
Institute in Houston. If you have any of this information please
respond.
Since there has been some discussion about Dr. Burzynski and antineoplastons, I thought some members of the group might be interested in the following news release. Bill
*********
May 26, 1998
Source: Business Wire
Burzynski Research Institute Announces Interim Cancer Drug Results
HOUSTON--(BUSINESS WIRE) via NewsEdge Corporation -- Burzynski Research Institute, Inc. (OTC bulletin board stock symbol:BZYR) today announced interim results from Phase II clinical trials of its experimental cancer drugs, Antineoplastons, in the treatment of brain cancer.
Used in combination, Antineoplastons A10 and AS2-1 produced responses (complete tumor elimination or greater than 50% reduction in tumor size) in 43 of 178 evaluable patients, for a response rate of 24.1 per cent. An additional 72 patients (40.5% of evaluable patients) experienced stable disease, meaning their tumors did not progress, or shrink more than 50%.
The two largest groups of patients suffered from glioblastoma multiforme (36.5%) and astrocytoma-type tumors (32%). Approximately 10% of patients had difficult-to-treat brain stem tumor locations.
"These results are exciting because conventional treatments are generally considered ineffective against primary malignant brain tumors," said Stanislaw Burzynski MD, PhD, the firm's founder and CEO. "What makes it all the more exciting is that these are responses in human brain cancers that are normally considered incurable and fatal. The patients with stable disease give us hope that even the most intractable cancers may become manageable chronic diseases."
The drugs represent a type of gene therapy that targets the signal path of errant ras oncogenes and the p53 tumor suppressor gene. Malfunctions in these genes are believed responsible for up to 60% of all human cancers.
"The drugs function as chemical microswitches, turning off the signal that makes cancer cells multiply endlessly, at the same time turning on the signal that tells the cells to undergo programmed cell death, or apoptosis," Burzynski said. "This is an information-age approach to cancer treatment because it uses information, rather than energy, to do the job."
Antineoplastons were well-tolerated by most patients. The most commonly reported adverse event was an elevated level of serum sodium. 1.3% of all clinical trial patients had elevations of 180 mEq/L or higher at or around the time of their deaths. Other adverse events included nausea, vomiting, allergic skin reactions, joint and muscle pain, and fatigue, and occurred in a small percentage of patients.
Burzynski believes the company now has enough data to apply for FDA approval. An NDA (New Drug Application) could be filed by the end of this year.
CONTACT: Burzynski Research Institute Inc., Houston | Dr. Stanislaw Burzynski, 281/597-0111 | www.cancermed.com | www.burzynskipatientgroup.org | or | Dean Mouscher, 773/404-0486
--------------------------------------------------------------------------------
William J. Comcowich, President, UltiTech, Inc. / Medicine OnLine
Foot of Broad Street, Stratford, CT. 06497 203-375-7300 The Ultimate in Multimedia and Internet Solutions ------------------------------------------------------------------------ This is an automatically-generated notice. If you'd like to be removed from the mailing list, please visit the Medicine-On-Line Discussion Forum at , or send an email message to: majordomo@lists.meds.com with the subject line blank and the body of the message containing the line: unsubscribe mol-cancer your-email-address where the phrase your-email-address is replaced with your actual email address. ------------------------------------------------------------------------
